Abstract
An 18-year old man presented to University College London Hospital (UCLH) in April, 2016, with stage IIIB classical Hodgkin lymphoma. He received chemotherapy and autologous haematopoietic stem-cell transplantation (HSCT) for primary progressive disease (details of treatment regimens are presented on appendix p 1). In January, 2017, he had a first relapse, for which he received brentuximab vedotin and reduced intensity conditioning haploidentical, allogeneic HSCT. He had a second relapse in May, 2018.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
